- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Knowledge Graph Search feature is available on CiNii Labs
- Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
Two cases of Embryonal tumor with Multilayered Rosettes (ETMRs) treated with high-dose chemotherapy and bevacizumab combined with dose escalation radiotherapy
-
- Maruyama Kazutaka
- Department of Pediatrics, Juntendo University Faculty of Medicine
-
- Kusano Shimpei
- Department of Pediatrics, Juntendo University Faculty of Medicine
-
- Fujiwara Megumi
- Department of Pediatrics, Juntendo University Faculty of Medicine
-
- Yaguchi Akinori
- Department of Pediatrics, Juntendo University Faculty of Medicine
-
- Ishibashi Takeshi
- Department of Pediatrics, Juntendo University Faculty of Medicine
-
- Tomita Osamu
- Department of Pediatrics, Juntendo University Faculty of Medicine
-
- Fujimura Junya
- Department of Pediatrics, Juntendo University Faculty of Medicine
-
- Suzuki Mario
- Department of Neurosurgery, Juntendo University Faculty of Medicine
-
- Kondo Akihide
- Department of Neurosurgery, Juntendo University Faculty of Medicine
-
- Shimizu Toshiaki
- Department of Pediatrics, Juntendo University Faculty of Medicine
Bibliographic Information
- Other Title
-
- 大量化学療法と放射線治療後の再発に,再手術および再照射とBevacizumab投与を行ったEmbryonal tumor with Multilayered Rosettesの2例
Search this article
Description
<p>Embryonal tumor with Multilayered Rosettes (ETMRs) has the worst prognosis among fetal brain tumors. There is no established standard of care, and multidisciplinary treatment that includes a combination of surgery, radiation therapy, and multidrug chemotherapy is often performed empirically. We encountered two cases of ETMR with different outcomes after multidisciplinary treatment, including surgery, radiation therapy, and chemotherapy for medulloblastoma. One patient developed local recurrence one month after treatment and underwent re-operation, re-irradiation, and bevacizumab (BEV) therapy and remained in remission for four years. The other patient developed three recurrences, including those during treatment, and underwent re-operation and additional radiotherapy with BEV but died 16 months after onset. Re-operation and re-irradiation for the recurrence of ETMR may be useful prolonging survival, and BEV therapy may be useful for preventing or suppressing the progression of radiation necrosis associated with an increased cumulative radiation dose.</p>
Journal
-
- The Japanese Journal of Pediatric Hematology / Oncology
-
The Japanese Journal of Pediatric Hematology / Oncology 59 (3), 304-308, 2022
The Japanese Society of Pediatric Hematology / Oncology
- Tweet
Details 詳細情報について
-
- CRID
- 1390012390812497152
-
- ISSN
- 21895384
- 2187011X
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
-
- Abstract License Flag
- Disallowed